Paid-in Capital Increase Decision
올릭스
226950
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2414
Risk-adjusted indicator based on 2414 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Board Resolution Date: June 29, 2026
- • Issuance Price Calculation: 6.912% premium applied to reference price
- • Purpose of Funds: Not specified in detail, but for operational funds, facility funds, etc.
AI Analysis Summary
OliX Pharmaceuticals, Inc. announced a decision on a paid-in capital increase via a third-party allocation, with the board resolution dated June 29, 2026. The issuance price for common shares will be determined by applying a 6.912% premium to the reference stock price, which is the lower of the recent day's weighted average price and the arithmetic average of 1-month, 1-week, and recent day weighted average prices. This adjustment is due to a change in the payment date for BOLD (Business Opportunities for L'Oreal Development) from a previous resolution on June 1, 2026, maintaining the same fixed issuance price. The specific number of shares, total funding amount, and detailed use of funds are not yet disclosed, limiting a full assessment of dilution and financial impact. The company states the funds are for general purposes such as facility and operational funds.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.